Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: akebia.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2025 | $8.00 | Buy | H.C. Wainwright |
| 4/28/2025 | $7.00 | Outperform | Leerink Partners |
| 4/1/2025 | $6.00 | Buy | Jefferies |
| 11/29/2023 | $4.00 | Buy | BTIG Research |
| 8/28/2023 | $3.75 | Neutral → Buy | H.C. Wainwright |
| 5/31/2023 | $2.00 → $4.00 | Neutral → Overweight | Piper Sandler |
| 3/31/2022 | $10.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
| 3/31/2022 | Buy → Hold | Needham | |
| 3/31/2022 | $6.00 → $2.00 | Buy → Neutral | Mizuho |
| 3/31/2022 | $6.00 → $2.00 | Overweight → Neutral | Piper Sandler |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
Fastest customizable press release news feed in the world
Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on Wednesday, August 13 at 1:30 PM EDT. The conference will take place August 12-14, 2025 in Boston. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmace
CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo® (vadadustat). The VOCAL trial, conducted within DaVita clinics, aims to generate data to evaluate the efficacy and safety of three times per week (TIW) dosing of vadadustat compared to standard of care erythropoiesis-stimulating agents (ESA) in patients with anemia of CKD receiving in-center hemodialysis. "Our team and partners within the dialysis community share a commitment to improvin
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia's common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.69 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of th
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the confere
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14 at 10:00 AM EDT. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of p
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 141,800 shares of Akebia's common stock on June 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.64 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of th
CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society of Nephrology (JASN) has published pre-specified analyses for the U.S. and non-U.S. patient subgroups from the vadadustat global phase 3 clinical program, which included two trials in patients with dialysis-dependent chronic kidney disease (DD-CKD; INNO2VATE) and two trials in patients with non–dialysis-dependent CKD (NDD-CKD; PRO2TECT). The vadadustat global phase 3 clinical trials were open-label, randomized, noninferiority trials that c
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 137,000 shares of Akebia's common stock on May 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.03 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of th
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 8:45 AM EDT. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. The Jefferies Global Healthcare Conference will take place June 3-5, 2025, in New York City. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmace
S-8 - Akebia Therapeutics, Inc. (0001517022) (Filer)
10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)
8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)
8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
SCHEDULE 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)
DEFA14A - Akebia Therapeutics, Inc. (0001517022) (Filer)
DEF 14A - Akebia Therapeutics, Inc. (0001517022) (Filer)
8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $8.00
Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00
Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00
BTIG Research resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $4.00
H.C. Wainwright upgraded Akebia Therapeutics from Neutral to Buy and set a new price target of $3.75
Piper Sandler upgraded Akebia Therapeutics from Neutral to Overweight and set a new price target of $4.00 from $2.00 previously
H.C. Wainwright downgraded Akebia Therapeutics from Buy to Neutral and set a new price target of $2.00 from $10.00 previously
Needham downgraded Akebia Therapeutics from Buy to Hold
Mizuho downgraded Akebia Therapeutics from Buy to Neutral and set a new price target of $2.00 from $6.00 previously
Piper Sandler downgraded Akebia Therapeutics from Overweight to Neutral and set a new price target of $2.00 from $6.00 previously
Live Leadership Updates
CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut
CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt
Live finance-specific insights
Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the confere
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the conference ca
Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2024 and recent business highlights. As previously announced, Vafseo® (vadadustat) shipments to customers began Januar
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live web
Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for VafseoVafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System codeAkebia to Host Conference Call at 8:00 a.m. ET on November 7CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2024, and recent business highlights.
Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. EST CAMBRIDGE, Mass., Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, prior to the open of financial markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization
Vafseo® (vadadustat) Tablets market availability on track for January 2025 TDAPA application submission and WAC pricing announcement for Vafseo complete Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 millionAkebia to host conference call at 8:00 a.m. ET on August 8 CAMBRIDGE, Mass., Aug. 8, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2024, and recent business highlights. During the quarter, Akebia made significant progress across multiple initiatives related to the commerci
Akebia to Host Conference Call on August 8, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, prior to the open of financial markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therap
Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve economicsAnnounced Vafseo WAC pricing of $1,278 for a 30-day supplySubmitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025Akebia to host investor conference call at 8:00 a.m. ET on July 11, 2024 CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced key updates pertaining to the commercial launch of Vafs
This live feed shows all institutional transactions in real time.
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)